Dymista in Chinese Adolescents

Starting soon · Phase 4

Conditions studied: Allergic Rhinitis Due to Allergens

In brief

The purpose of this study is to determine if the investigational drug product ("study drug"), Dymista (azelastine hydrochloride and fluticasone propionate) nasal spray is safe and effective in the treatment of allergic rhinitis in Chinese adolescents with or without ocular symptoms. It is expected that approximately, 100 participants will be enrolled in this study. The study will be performed in approximately 15 clinical study centers in China. Study participants will be asked to complete up to 3 study visits at the study site and a follow-up by telephone. Treatment Assignment: All participants will receive a bottle of Dymista nasal spray and should administer it at a dose of twice daily (one spray per nostril), once in the morning and once in the afternoon, the doses will be approximately 12 hours apart. The liquid medicine is sprayed out in a mist after actuator is pressed. You will administer the trial intervention for 14 (+5) days. Regular study schedule: * Screening visit (Visit 1, Day -7 to 1) * Baseline visit (Visit 2, Day 1) * Visits 3 (End of Trial (EOS), Day 15 (+5)) * Follow-up (Telephone Call, within 14 (+5) days after the last administration of Dymista) The participation may last approximately 29 days to 60 days (depending on extended periods of screening, treatment, and follow-up).

Key facts

Study ID

NCT07597473

Run by

Viatris Inc.

People needed

100

Starts

2026-04-30

Expected to finish

2027-03-01

Last updated by the study team

2026-05-19

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female Chinese participants aged 12 to 17 years (inclusive) at screening.
• informed consent/assent from participants and from parent(s) or legal guardian(s) in compliance with local requirements.
• Participants must have moderate-to-severe seasonal and/or perennial AR with or without ocular symptoms, defined as rhinitis with one or more of the following being present:
• Sleep disturbance
• Impairment of daily activities, leisure, and/or sport
• Impairment of learning or work
• Troublesome symptoms
• Moderate to severe seasonal and/or perennial AR with or without ocular symptoms in whom intranasal antihistamines or glucocorticoid monotherapy is not considered sufficient at the discretion of the Investigator and/or designee.
• Presence of Immunoglobulin E (IgE)-mediated hypersensitivity to one or more aeroallergens present in the current participant environment, confirmed by a positive response to an established standard diagnostic test at the site within the last year (before treatment start). Accepted diagnostic tests include:
• Skin prick tests
• Specific IgE tests Diagnosis of hypersensitivity will follow the current clinical practice at study sites.
• Acute allergic rhinitis symptoms at the day of inclusion evidenced by a 12-hour reflective TNSS ≥8 out of 12.
• General good health and free of any disease or concomitant treatment that may increase the risk associated with study participation or investigational product administration or could interfere with the interpretation of the study results as determined by the Investigator or the Sponsor's medical officer. When in doubt, the Investigator should confer with the Sponsor's medical monitor or designee to determine eligibility for the study.
• Negative pregnancy test in females with childbearing potential.
• Ability to understand and follow the instructions for using Dymista nasal spray according to the participant information leaflet.
• Willingness to complete and return the Patient Diary and comply with the study requirements.

You may not qualify if…

• Safety concerns:
• Known allergic reaction from and/or intolerance to Dymista, azelastine hydrochloride, fluticasone propionate nasal sprays or any of the ingredients
• Pregnancy/planned pregnancy or breastfeeding during this study
• Lack of suitability for the study:
• Participants or parent(s)/legal guardian(s) are not able to fulfil study requirements according to Investigator's opinion.
• Clinically significant nasal or sinus disease that may affect intranasal drug deposition, including but not limited to nasal mucosal erosion/ulceration or septum perforation (Grade 1b - 4), significant polyposis, marked septum deviation, active or recurrent sinusitis (>3 episodes/year), or nasal/sinus surgery within the past 12 months.
• The use of any investigational drug within 30 days or within 5 half-lives of the investigational drug (whichever is longer) prior to inclusion. No other investigational products are permitted for use during the conduct of this study.
• Respiratory tract infections within 7 days prior to inclusion.
• Asthma (with the exception of mild intermittent asthma). Participants with mild intermittent asthma who only require short-acting inhaled bronchodilators and who do not have nocturnal awakening as a result of asthma are eligible for enrolment.
• Current use or expected requirement of ritonavir or strong P4503A4 inhibitors including cobicistat-containing products.
• Specific immunotherapy within 6 months prior to Screening Visit. If the participant received immunotherapy a 6-month washout period is required following the last dose of immunotherapy.
• Use of the following medications or therapies within the time period specified below prior to Screening Visit:
• Medication/Therapy Time Prior to Screening Visit
• Antihistamines: including oral, ocular, intranasal, prescribed and over the counter, biological active supplements, cold preparation, sleep aids containing such components (5 days)
• Oral and intranasal anticholinergic agents including ipratropium nasal spray (5 days)
• Inhaled, oral corticosteroids (30 days)
• Intranasal corticosteroids (14 days)
• Systemic steroids, includes oral, injected, intravenous [IV], (30 days)
• Ocular corticosteroids (7 days)
• Leukotriene inhibitors (14 days)
• Oral antibiotics for Respiratory tract infections (14 days)
• Cromolyn compounds, all mast cell stabilizers (14 days)
• Ephedrine or pseudoephedrine containing products (5 days)
• Decongestants including cold preparations (5 days)
• Traditional Chinese Medicines (TCM) for treatment of AR with known active ingredient, e.g. antihistamines, ephedrine or pseudoephedrine, (5 days)

Where it is running

• Capital Center for Children's Health, Capital Medical University — Beijing, China
• Hunan Provincial People's Hospital — Changsha, China
• The Third XiangyaHospital of Central South University — Changsha, China
• Sichuan Provincial People's Hospital — Chengdu, China
• Dalian Municipal Central Hospital — Dalian, China
• Affiliated Hangzhou First people's hospital, School of Medicine, Westlake University — Hangzhou, China
• Children's Hospital of Zhejiang University School of Medicine — Hangzhou, China
• The Second Affiliated Hospital of Nanchang University — Nanchang, China
• Eye & Ent Hospital of Fudan University — Shanghai, China
• The Second Affiliated Hospital of Shanxi Medical University — Taiyuan, China
• Tianjin Union Medical Center/Nankai University Affiliated Hospital — Tianjin, China
• The Central Hospital of Wuhan — Wuhan, China
• Union Hospital of Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China
• The Second Affiliated Hospital of Xi'an JiaotongUniversity(XibeiHospital) — Xi'an, China
• Central Hospital of Zibo — Zibo, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.